FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office
Drug industry officials and analysts praised the FDA’s plans to streamline regulation of “biosimilars,� which are cheaper alternatives to biologic drugs. But patents that block such drugs from the U.S. market are getting harder to fight.